Biomerica (BMRA) Competitors $2.98 +0.03 (+1.02%) Closing price 04:00 PM EasternExtended Trading$2.99 +0.01 (+0.34%) As of 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMRA vs. RVPH, CASI, THAR, ASBP, ITRM, KZR, DARE, TENX, PMN, and MIRAShould you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include Reviva Pharmaceuticals (RVPH), CASI Pharmaceuticals (CASI), Tharimmune (THAR), Aspire Biopharma (ASBP), Iterum Therapeutics (ITRM), Kezar Life Sciences (KZR), Dare Bioscience (DARE), Tenax Therapeutics (TENX), Promis Neurosciences (PMN), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry. Biomerica vs. Its Competitors Reviva Pharmaceuticals CASI Pharmaceuticals Tharimmune Aspire Biopharma Iterum Therapeutics Kezar Life Sciences Dare Bioscience Tenax Therapeutics Promis Neurosciences MIRA Pharmaceuticals Biomerica (NASDAQ:BMRA) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment. Which has more volatility & risk, BMRA or RVPH? Biomerica has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of -0.04, indicating that its stock price is 104% less volatile than the S&P 500. Do institutionals & insiders believe in BMRA or RVPH? 22.3% of Biomerica shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 15.0% of Biomerica shares are owned by insiders. Comparatively, 27.2% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher valuation and earnings, BMRA or RVPH? Biomerica has higher revenue and earnings than Reviva Pharmaceuticals. Biomerica is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomerica$5.31M1.58-$4.97M-$2.32-1.28Reviva PharmaceuticalsN/AN/A-$29.92M-$0.65-0.68 Does the media prefer BMRA or RVPH? In the previous week, Biomerica had 3 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 5 mentions for Biomerica and 2 mentions for Reviva Pharmaceuticals. Biomerica's average media sentiment score of 1.02 beat Reviva Pharmaceuticals' score of 0.59 indicating that Biomerica is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomerica 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Reviva Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer BMRA or RVPH? Reviva Pharmaceuticals has a consensus price target of $5.20, indicating a potential upside of 1,075.67%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Biomerica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomerica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Reviva Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Is BMRA or RVPH more profitable? Reviva Pharmaceuticals has a net margin of 0.00% compared to Biomerica's net margin of -93.64%. Reviva Pharmaceuticals' return on equity of 0.00% beat Biomerica's return on equity.Company Net Margins Return on Equity Return on Assets Biomerica-93.64% -98.97% -69.88% Reviva Pharmaceuticals N/A N/A -259.17% SummaryReviva Pharmaceuticals beats Biomerica on 10 of the 16 factors compared between the two stocks. Get Biomerica News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRA vs. The Competition Export to ExcelMetricBiomericaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.39M$2.84B$5.79B$10.15BDividend YieldN/A56.65%5.69%4.61%P/E Ratio-1.2823.5374.5925.92Price / Sales1.58534.82454.0285.55Price / CashN/A169.2537.0859.91Price / Book1.855.3712.156.29Net Income-$4.97M$32.95M$3.28B$270.85M7 Day Performance8.36%1.31%0.98%3.35%1 Month Performance-0.33%8.31%7.20%6.40%1 Year Performance22.09%0.29%63.06%28.21% Biomerica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRABiomerica0.8341 of 5 stars$2.98+1.0%N/A+18.3%$8.39M$5.31M-1.2860Positive NewsShort Interest ↓RVPHReviva Pharmaceuticals2.9989 of 5 stars$0.45+0.7%$5.20+1,047.9%-65.9%$30.80MN/A-0.705CASICASI Pharmaceuticals3.7727 of 5 stars$2.42+4.8%$4.00+65.3%-69.1%$30.38M$28.54M-0.85180THARTharimmune2.4631 of 5 stars$5.14-13.7%$17.00+231.1%+6.1%$29.49MN/A-0.852Short Interest ↑Gap UpASBPAspire BiopharmaN/A$0.57-0.2%N/AN/A$28.43MN/A0.00N/APositive NewsITRMIterum Therapeutics2.8487 of 5 stars$0.64-6.0%$9.00+1,315.1%-32.8%$28.40MN/A-0.7510Positive NewsShort Interest ↓KZRKezar Life Sciences3.864 of 5 stars$3.86-2.3%$9.00+133.2%-31.1%$28.37M$7M-0.4060DAREDare Bioscience2.3002 of 5 stars$2.03+0.2%$12.00+492.6%-35.3%$27.30M$10K-0.9530Positive NewsShort Interest ↓TENXTenax Therapeutics2.2728 of 5 stars$5.98-0.3%$17.00+184.5%+64.2%$27.25MN/A-6.499PMNPromis Neurosciences3.6842 of 5 stars$0.52-2.9%$4.33+727.0%-66.0%$27.15MN/A-2.505Positive NewsShort Interest ↓MIRAMIRA Pharmaceuticals3.0566 of 5 stars$1.39+1.8%$17.00+1,119.5%+17.7%$26.51MN/A-2.842News CoveragePositive NewsShort Interest ↓Gap Up Related Companies and Tools Related Companies Reviva Pharmaceuticals Alternatives CASI Pharmaceuticals Alternatives Tharimmune Alternatives Aspire Biopharma Alternatives Iterum Therapeutics Alternatives Kezar Life Sciences Alternatives Dare Bioscience Alternatives Tenax Therapeutics Alternatives Promis Neurosciences Alternatives MIRA Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRA) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomerica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BMRA Stock Alerts